Coronavirus Trend Helps Improve Krka’s EBIT By 85%
As Prescription Pharmaceutical Sales Shoot Up In Q1
Slovenian firm Krka saw an increased demand for its prescription product portfolio during the quarter, which boosted group sales by more than a fifth. The company’s bottom line was a slightly more complex tale, as currency exposure in Russia wiped out significant gains in Krka’s EBIT.
You may also be interested in...
Krka Singles Out Launch Opportunities As Prescription Sales Tumble
Slovenian firm Krka saw sales and profits down in the first quarter of 2021 as operations normalized to some degree following an extraordinary Q1 last year.
Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Juno Looks To Shore Up Canada Supply Chains With Omega Deal
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.